BioSpace News Archive

The world-renowned HGH Infrared Systems is developing its brand image and communication strategy to better reflect its position as a global leader in the optronics market.

Evotec and the mark foundation form first collaboration together to advance oncology assets based on evotec’s new allosteric inhibitor platform “Targetallomod”

Therigy announced that the company will present a poster from its recently completed quality initiative: “Improving Quality of Care in Rheumatoid Arthritis Utilizing Hospital-Based Specialty Pharmacies in Monitoring Disease Activity,” at the AMCP Managed Care and Specialty Pharmacy 2019 Annual Meeting being held March 25-28, 2019 in San Diego, California.

Today, Celgene submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its ozanimod for adults with relapsing forms of multiple sclerosis (RMS).

YL Biolologics Ltd., Yoshindo Inc. and Teijin Ltd. have announced that on March 26, 2019, YL Biologics obtained manufacturing and sales approval for Etanercept biosimilar, an agent for anti-rheumatoid arthritis and polyarticular-course juvenile idiopathic arthritis which YL Biologics has developed globally.

St. Louis, Missouri is one of the fastest-growing and top-ranked emerging life sciences markets in the U.S., ranking sixth in a recent CBRE Research report.

The prevalence of using antidepressants and proton pump inhibitors increases after the diagnosis of Alzheimer’s disease, according to a doctoral dissertation from the University of Eastern Finland.

ELATUR® DPT enables fast and simple production of flexible PVC products such as floor and wall coverings

Theralase Technologies Inc. is pleased to announce that the results of the Phase Ib clinical study will be presented at the 17th International Photodynamic Association World Congress, to be held in Cambridge, Massachusetts from June 28th to July 4th, 2019.

The Massachusetts Mesothelioma Victims Center is one of the best branded sources on the Internet when it comes to the best possible compensation for a US Navy Veteran, or US Navy shipyard worker in Massachusetts who has recently been diagnosed with mesothelioma or asbestos exposure lung cancer.